William Blair Comments on Incyte’s Q1 Earnings (NASDAQ:INCY)

Incyte Co. (NASDAQ:INCY) – Stock analysts at William Blair cut their Q1 2025 EPS estimates for Incyte in a report released on Monday, April 14th. William Blair analyst M. Phipps now anticipates that the biopharmaceutical company will earn $0.76 per share for the quarter, down from their previous estimate of $0.77. William Blair currently has a “Market Perform” rating on the stock. The consensus estimate for Incyte’s current full-year earnings is $4.86 per share.

Other analysts have also issued research reports about the stock. Citigroup decreased their price target on shares of Incyte from $97.00 to $88.00 and set a “buy” rating for the company in a research note on Tuesday, February 11th. Stifel Nicolaus boosted their target price on shares of Incyte from $75.00 to $77.00 and gave the stock a “hold” rating in a research report on Monday, February 10th. Truist Financial dropped their price target on shares of Incyte from $74.00 to $72.00 and set a “hold” rating on the stock in a research report on Tuesday, March 18th. Wells Fargo & Company boosted their price objective on Incyte from $68.00 to $70.00 and gave the stock an “equal weight” rating in a report on Thursday, December 19th. Finally, Royal Bank of Canada decreased their price target on Incyte from $70.00 to $68.00 and set a “sector perform” rating for the company in a report on Tuesday, February 11th. One investment analyst has rated the stock with a sell rating, thirteen have given a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $74.88.

Incyte Trading Up 0.8 %

NASDAQ INCY opened at $58.21 on Wednesday. Incyte has a 52 week low of $50.35 and a 52 week high of $83.95. The business has a 50 day moving average price of $65.01 and a 200-day moving average price of $69.37. The company has a quick ratio of 1.94, a current ratio of 1.97 and a debt-to-equity ratio of 0.01. The company has a market cap of $11.27 billion, a price-to-earnings ratio of 215.60, a P/E/G ratio of 0.41 and a beta of 0.89.

Incyte (NASDAQ:INCY) last posted its quarterly earnings results on Monday, February 10th. The biopharmaceutical company reported $1.09 earnings per share for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.48). Incyte had a return on equity of 0.05% and a net margin of 0.77%.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the stock. Quintet Private Bank Europe S.A. purchased a new position in Incyte during the fourth quarter valued at approximately $26,000. Global X Japan Co. Ltd. boosted its holdings in Incyte by 144.7% in the 4th quarter. Global X Japan Co. Ltd. now owns 389 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 230 shares during the period. R Squared Ltd purchased a new position in shares of Incyte during the 4th quarter valued at $30,000. Raiffeisen Bank International AG bought a new position in shares of Incyte in the fourth quarter worth $34,000. Finally, Blue Trust Inc. raised its position in shares of Incyte by 124.6% in the fourth quarter. Blue Trust Inc. now owns 593 shares of the biopharmaceutical company’s stock worth $39,000 after buying an additional 329 shares in the last quarter. Institutional investors own 96.97% of the company’s stock.

Insiders Place Their Bets

In other Incyte news, EVP Sheila A. Denton sold 599 shares of the business’s stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $69.99, for a total transaction of $41,924.01. Following the sale, the executive vice president now owns 25,848 shares of the company’s stock, valued at $1,809,101.52. The trade was a 2.26 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Barry P. Flannelly sold 19,807 shares of the firm’s stock in a transaction on Friday, March 14th. The stock was sold at an average price of $67.69, for a total value of $1,340,735.83. Following the completion of the transaction, the executive vice president now directly owns 33,567 shares of the company’s stock, valued at $2,272,150.23. The trade was a 37.11 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 46,827 shares of company stock valued at $3,322,618 over the last ninety days. 17.60% of the stock is currently owned by insiders.

Incyte Company Profile

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis.